Clene to Present at Two Investor Conferences in October

Clene Inc. (NASDAQ: CLNN), a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, has announced its participation in two investor conferences this month. The company, which specializes in improving mitochondrial health and protecting neuronal function, will present at the 2024 Maxim Healthcare Virtual Summit and the ThinkEquity Conference 2024.

On October 15, 2024, at 2:30 p.m. ET, Clene will deliver a virtual presentation at the Maxim Healthcare Virtual Summit, a three-day event running from October 15-17. Later in the month, on October 30, 2024, the company will present at 3:30 p.m. ET during the ThinkEquity Conference 2024, held at the Mandarin Oriental Hotel in New York.

These presentations offer Clene an opportunity to showcase its progress in developing treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). The company's flagship investigational therapy, CNM-Au8®, targets mitochondrial function and the NAD pathway while reducing oxidative stress, potentially improving central nervous system cells' survival and function.

Clene's participation in these investor conferences is significant for several reasons. First, it provides a platform for the company to update investors and the broader market on its clinical progress and pipeline developments. This visibility could be crucial for attracting investment and partnerships in the competitive biopharmaceutical sector.

Second, the conferences offer Clene the chance to highlight the potential impact of its research on patients suffering from neurodegenerative diseases. With millions affected by conditions like ALS and MS worldwide, advancements in treatment could have far-reaching implications for public health and quality of life.

Lastly, Clene's presence at these events underscores the growing interest in mitochondrial health as a target for treating neurodegenerative diseases. As the company continues to advance its novel approach, it may contribute to shifting paradigms in how these conditions are understood and treated.

Investors and industry observers will likely be watching closely for any new information or insights that emerge from Clene's presentations, as they could provide valuable indications of the company's future prospects and the potential impact of its research on the field of neurodegenerative disease treatment.